Al-Dawaa Medical Services Company (4163.SR)
SAR 79.6
(-0.5%)
SAR 79.6
(-0.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 329.22 Million SAR | 7.78% |
| 2022 | 305.44 Million SAR | 27.73% |
| 2021 | 239.14 Million SAR | -2.96% |
| 2020 | 246.43 Million SAR | 5.67% |
| 2019 | 233.2 Million SAR | 2.13% |
| 2018 | 228.33 Million SAR | 88.87% |
| 2017 | 120.89 Million SAR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 95.32 Million SAR | 3.22% |
| 2024 Q2 | 95.87 Million SAR | 0.58% |
| 2023 Q2 | 89.33 Million SAR | 17.15% |
| 2023 Q1 | 76.25 Million SAR | -14.81% |
| 2023 FY | 329.22 Million SAR | 7.78% |
| 2023 Q4 | 92.35 Million SAR | 29.56% |
| 2023 Q3 | 71.28 Million SAR | -20.21% |
| 2022 Q4 | 89.51 Million SAR | 85.89% |
| 2022 Q3 | 48.15 Million SAR | -40.31% |
| 2022 Q2 | 80.67 Million SAR | -7.39% |
| 2022 Q1 | 87.1 Million SAR | 26.11% |
| 2022 FY | 305.44 Million SAR | 27.73% |
| 2021 Q3 | 38.29 Million SAR | -27.66% |
| 2021 Q2 | 52.93 Million SAR | -32.85% |
| 2021 Q4 | 69.07 Million SAR | 80.38% |
| 2021 FY | 239.14 Million SAR | -2.96% |
| 2021 Q1 | 78.83 Million SAR | -6.13% |
| 2020 Q2 | 55.35 Million SAR | 41.09% |
| 2020 FY | 246.43 Million SAR | 5.67% |
| 2020 Q4 | 83.98 Million SAR | 0.0% |
| 2020 Q3 | 83.98 Million SAR | 51.74% |
| 2020 Q1 | 39.22 Million SAR | 0.0% |
| 2019 FY | 233.2 Million SAR | 2.13% |
| 2018 FY | 228.33 Million SAR | 88.87% |
| 2017 FY | 120.89 Million SAR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 65.82 Million SAR | -400.132% |
| Nahdi Medical Company | 892.61 Million SAR | 63.117% |
| Al-Razi Medical Co. | 685.96 Thousand SAR | -47893.985% |
| Almujtama Alraida Medical Co. | 11.39 Million SAR | -2789.71% |